drugset / Trial / NCT06668441

Minimally Invasive Surgery and rhTNK-tPA for Intracerebral Hemorrhage Evacuation

NCT06668441

Phase 1 Completed 12 enrolled Beijing Tiantan Hospital
NaSequentialOpen-labelTreatment

Summary

The purpose of this trial is to determine the safety of using a combination of robot-assisted stereotactic puncture and clot lysis with rhTNK-tPA to remove intracerebral hemorrhage (ICH) and to provide dose evidence for a phase III clinical trial.

Timeline

Start
2024-11-04
Primary completion
2025-01-27
Completion
2025-01-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenecteplase Protein / enzyme biologic 0.001 mg/ml Other
Subject Tenecteplase Protein / enzyme biologic 0.003 mg/ml Other
Subject Tenecteplase Protein / enzyme biologic 0.009 mg/ml Other